Table 4.
Clinical trials of monotherapy with conventional IFN or pegylated IFN in hemodialysis patients with chronic hepatitis C.
| Period | Patients number | Antiviral Agent | Doses of IFN or Peg-IFN | SVR | |
|---|---|---|---|---|---|
| Degos et al. [132] | 2001 | 37 | IFN α | 3 MU three times weekly | 19% |
| Mukherjee et al. [152] | 2003 | 9 | Peg-IFN-α2b | 1 mcg/kg/week | 22% |
| Ozdemir et al. [133] | 2004 | 20 | IFN α | 3–6 MU three times weekly | 40% |
| Rivera et al. [134] | 2005 | 27 | IFN α (n = 20) Peg-IFN-α2a (n = 7) |
3 MU three times weekly 135 mcg/week |
40% |
| Mahmoud et al. [61] | 2005 | 18 | IFN α | 3 MU three times weekly | 44% |
| Grgurevic et al. [135] | 2006 | 15 | IFN α | 3 × 3 MU/week (n = 8) 3 × 5 MU/week for 3 months, then 1 × 5 MU/week for another 3 months (n = 7) |
40% |
| Rocha et al. [136] | 2006 | 46 | IFN α | 3 MU three times weekly | 22% |
| Sporea et al. [153] | 2006 | 10 | Peg-IFN-α2a | 180 mcg/week | 30% |
| Russo et al. [151] | 2006 | 16 | Peg-IFN-α2b | 1 mcg/kg/week (n = 9), 0.5 mcg/kg/week (n = 7) | 12.5% |
| Covic et al. [154] | 2006 | 78 | Peg-IFN-α2a | 135 mcg/week | 14% |
| Espinosa et al. [36] | 2007 | 16 | Peg-IFN-α2a (n = 7) Peg-IFN-α2b (n = 9) |
1.5 mcg/week (n = 9), 135 mcg/kg/week (n = 7) |
25% |
| Casanovas-Taltavull et al. [155] | 2007 | 12 | Peg-IFN-α2a | 135 mcg/week | 25% |
| Ucmak et al. [156] | 2008 | 12 | Peg-IFN-α2a | 135 mcg/week | 50% |
| Sikole et al. [157] | 2008 | 14 | Peg-IFN-α2a | 135 mcg/week | 41% |
| Liu et al. [158] | 2008 | 25 | Peg-IFN-α2a | 135 mcg/week | 48% |
| Ayaz et al. [159] | 2008 | 22 | Peg-IFN-α2a | 135 mcg/week | 50% |
| Akhan et al. [160] | 2008 | 12 | Peg-IFN-α2a | 135 mcg/week | 50% |
| Werner et al. [168] | 2010 | 22 | Peg-IFN-α2a (n = 9) Peg-IFN-α2b (n = 13) |
180 mcg/week 1.5 mcg/kg/week 1 mcg/kg/week (1 patient) |
45% |
IFN: interferon; MU: million units; Peg-IFN: pegylated interferon; SVR: sustained virological response.